Understanding the Health System Conditions Affecting the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia in Clinical Practice: A US Healthcare Provider Survey

• Published in: Neuropsychiatric disease and treatment Vol. 18; pp. 1479 - 1493
• Main Authors: Zhdanava, Maryia, Starr, H. Lynn, Lefebvre, Patrick, Totev, Todor I, Shah, Aditi, Sheng, Kristy, Pilon, Dominic
• Format: Journal Article
• Language: English
• Published: Auckland Dove Medical Press Limited 01.01.2022; Taylor & Francis Ltd; Dove; Dove Medical Press
• Subjects: Antipsychotic drugs; Antipsychotics; Caregivers; Clinical medicine; Coronaviruses; COVID-19; Dosage and administration; Drug therapy; Drugs; Health care; healthcare providers; Hospitalization; long-acting injectable antipsychotics; Mental disorders; Nurse practitioners; Nurses; Original Research; Pandemics; Patients; Practice; Prescribing; prescribing patterns; Professionals; Psychiatrists; Psychiatry; Psychologists; Psychotropic drugs; Questionnaires; Review boards; Schizophrenia; Social workers; Surveys; United States; United States > US

Purpose: To describe factors that enable the routine use of long-acting injectable antipsychotics (LAIs) for appropriate patients in the current clinical practice, including changes in LAI prescribing due to the COVID-19 pandemic and expectations for prescribing in 2021 in the United States (US). Me...